We help Atlantic Canada companies, industries and researchers use genomic insights and innovations to solve real-world problems.

Impactful investments

Genome Atlantic has consistently strived to drive meaningful impact through all our activities. Realizing the importance of quantifying this impact, we recently enlisted The Evidence Network to conduct a comprehensive Impact Assessment spanning the five-year period from 2018 to 2023. Their findings pointed to a remarkable return on investment and tangible outcomes:

  • Every public sector dollar invested in Genome Atlantic yielded $23 in applied R&D investment and $59 to GDP.
  • Genome Atlantic’s efforts enabled $60 million in new impact-driven genomics R&D – of which $21 million or roughly 30%, was private sector investment.
  • Total funds attracted by and invested in Genome Atlantic during the last five years resulted in an estimated $178.7 million of output, $122.2 million contributions to GDP, $8.9 million in provincial and federal tax revenues, and 927 jobs.

Please take a few minutes to read our Impact Assessment. Though concise, the report is packed with compelling data highlighting Genome Atlantic’s crucial role as a key driver of innovation and impact within Atlantic Canada.

Genome Atlantic is proud of our contributions to the region’s prosperity and well-being.  Our accomplishments are made possible by the support and dedication of our project partners and government funders at both federal and provincial levels, whose collaboration has been pivotal in driving our shared success.

Untitled design 2023 03 10t090115. 683 e1678453312746

Steve Armstrong, PhD
President & CEO
Genome Atlantic

Impacts At A Glance:

New Brunswick

Play Video

An update on our Impacts from our President and CEO Steve Armstrong

When MSX was first detected in P.E.I.’s Bedeque Bay in July 2024, alarm bells rang across Maritime Canada’s oyster sector. Now confirmed in New Brunswick too, the parasite threatens a regional industry valued at $58 million in P.E.I. alone. For Dr. Martin Mallet, co-owner of L’Étang Ruisseau Bar Ltée (ERB)/Mallet Oysters in Shippagan — the Maritimes’ largest oyster seed supplier — the best line of defence is clear: selective breeding powered by genomics. Genome Canada recently announced a $3.1M Genome Atlantic project  to support this work and put MSX-resistant seed in the hands of growers, faster.  Check out our press release and video interview with Dr. Mallet who is co-leading this initiative.

Genomics-driven selective breeding is key to developing MSX-resistant oyster seed — a vital long-term solution for the industry. But genomics is also being deployed for short-term solutions.  Through Genome Canada’s $800,000 eDNA Surveillance Initiative, Genome Atlantic is leading a regional project to develop early detection tools for MSX and Dermo in oyster-growing areas. Check out our video and news release about the project.

In Cape Breton’s Bras d’Or Lake, a genomics-powered comeback is underway. Biologist Dr. Rod Beresford is working with First Nations groups and other local experts to combine cutting-edge science with traditional knowledge in a bid to revive oyster operations devastated by MSX disease more than 20 years ago. With support from Genome Atlantic and others, Dr. Beresford is developing rapid detection tools using eDNA and exploring new growing methods – offering fresh hope for the industry and drawing strength from the insights of those who know the lake best. Check out our video and article to find out more.

Salmon aquaculture is an important and growing industry in New Brunswick, with the province responsible for about 60% of Atlantic Canada’s salmon production.  Supporting this vital industry is important to Genome Atlantic and over the years we have aligned with local industry, government and researchers to address many of the industry’s challenges while improving its sustainability.

This month the Government of Canada announced research support for yet another Genome Atlantic aquaculture initiative – a $4.7 Million Complex Gill Health Initiative that will focus on Complex Gill Disease (CGD), a growing health challenge for salmon farming operations in both the Pacific and North Atlantic.  This project, co-led by Genome Atlantic and Genome BC, will validate biomarkers of healthy and compromised gills of Atlantic salmon and use these to develop an early warning system for the development of gill disease on Atlantic salmon production sites across Canada. The resulting genomics-enabled tools for fish health will guide the management and intervention strategies for complex gill disease in Atlantic salmon.

We congratulate the coast-to-coast research team and acknowledge the generous support of project funders the Government of Canada through Genome Canada, the federal Department of Fisheries and Oceans, Genome BC, BC Salmon Farmers Association, Mitacs Canada, Memorial University, the University of Prince Edward Island, and industry partners Cermaq Canada, Grieg Seafood, and Cargill.

Genome Atlantic is proud to be a founding member of the recently formed Atlantic Tree Improvement Council (AtlanTIC), a pan-Atlantic collaborative of private and public sector organizations committed to realizing the economic and environmental benefits of tree improvement in Atlantic Canada through collaborative breeding, field testing, resource sharing and research.

In February, Nova Scotia’s Forestry Innovation Transition Trust provided funding to Genome Atlantic of $315,500 over four years to support The Atlantic Tree Improvement Council (AtlanTIC) to help support new field testing of tree improvement technologies such as genomics which have been shown to shorten breeding cycles and increase growth rate, wood quality, pest resistance and adaptation to climate change.

Adding genomics to the tree improvement toolkit can save considerable time and money for the forestry industry. For example, a recent genomics project that Genome Atlantic carried out in collaboration with a New Brunswick industry partner resulted in an estimated 10% increase in production of commercial spruce trees on a test tract of land where the project was conducted. The AtlanTIC collaborative will be a means for conducting more proof of concept applications of tree improvement technologies, and sharing the results with companies across the region.

Genome Atlantic is pleased to partner with AtlanTIC to help the forestry industry realize the economic and environmental benefits of tree improvement technologies.

The Chief Medical Officer of Canada has consistently highlighted the critical importance of COVID-19 testing capacity to support re-opening the economy, and genomic tools are proving to be invaluable in this regard. Genomics plays a vital role in detecting infections, tracking disease spread, and developing tests, vaccines and treatments. Genome Atlantic is working tirelessly to support initiatives that are responding to some of our biggest challenges in relation to the pandemic.

Genome Atlantic recently announced more than $300,000 in funding through Genome Canada’s COVID-19 Regional Genomics Initiative for two research projects – one focusing on biomarkers to predict disease severity, and the other piloting a simple, quick and inexpensive surveillance tool for screening COVID-19 in high-risk settings like long-term care facilities fish processing and meat packing plants, fishing boats, etc.

Pooling together our data about COVID-19 is one of the best, most effective ways that Canada can respond to current and future pandemics. The recent announcement of a $40 million Canadian COVID Genomics Network (CanCOGeN) is great news. CanCOGeN will undertake two related genomics projects to help us understand how the virus works, how it is evolving, and why people experience such different health outcomes. CanCOGeN will sequence the complete genomes of up to 10,000 patients and up to 150,000 viral samples and will build a bank of “virus to patient” data that will inform decision-making by public health authorities and support the development of therapies and vaccines. Of critical importance, CanCOGeN will establish and manage a framework of cross-Canada safe data sharing, coordination and analysis. CanCOGeN is led by Genome Canada in partnership with the six regional Genome Centres including Genome Atlantic, as well as national and provincial public health labs, genome sequencing centres, hospitals and universities.  In New Brunswick, Genome Atlantic is working with Vitalité Health Network as part of this collaborative initiative.

There are many pieces to the COVID-19 puzzle and genomics is helping us find the answers.  But how exactly? Genome Atlantic developed two short animated videos   to explain. (Scroll down the web page to Special Feature: Genomics in the battle against COVID-19.) Video #1, On the Trail of Covid-19, is about detecting infections and understanding how the virus mutates while the second video, The Race for a Vaccine, focuses on tracking mutations and developing vaccines and treatments. Please take a few minutes to watch them.  These videos are intended to provide a deeper understanding of how the scientific community has responded, while conveying well-founded hope.

Just as genomic technologies are critical for enabling necessary surveillance and testing so we can re-open our economy safely, they are also vital for driving economic recovery in New Brunswick’s key industry sectors such as agriculture, aquaculture and forestry, for supporting industries within Canada’s Ocean Supercluster, and for providing environmental monitoring tools that can help to guide regulators and expand vital industries in environmentally sustainable ways.

Our active projects with a New Brunswick focus currently total more than $7 million in solutions-driven R&D with another $6 million in new potential projects at various stages of business development.

Several years ago, New Brunswick forestry giant JD Irving Ltd. embarked on a project called FastTRAC to compare genomic selection and traditional breeding of white spruce. The results were impressive. Like other forestry companies, JDI uses selective breeding to naturally select superior, faster growing trees with the best traits for harvesting and industrial use. With conventional breeding practices, growers may have to wait 20 years before these traits can be assessed and the best trees chosen as breeding stock – but JDI estimates that genomics cut an estimated eight years from the process. This could translate into an increase in wood production of 10% in New Brunswick. Currently, Genome Atlantic is working with JDI and the New Brunswick Department of Natural Resources and Energy Development on a $6 million proposal for a follow-up FastTRAC2 project focusing on two other species important to eastern Canada: red and black spruce.

MORE Related News and Updates

Sign up for our free newsletter.

We will deliver SEQUENCE to your inbox. SEQUENCE highlights the latest genomics applications and research initiatives in Atlantic Canada. Subscribe to stay informed.

Read recent issues here.

Sign up for our free newsletter.

We will deliver SEQUENCE to your inbox. SEQUENCE highlights the latest genomics applications and research initiatives in Atlantic Canada. Subscribe to stay informed.

Read recent issues here.

What Our Clients Say?

“Access to genomic technology and the opportunity to work with genome Atlantic are crucial to the success of our program which has long term implication for both our company and the developing oyster industry.”

Dr. André Mallet

President, L’Étang Ruisseau Bar Ltd., Shippagan, N.B.

“From an institutional standpoint and as a researcher, being able to take a product and move it to commercialization in partnership with Genome Atlantic and Cold Ocean Salmon, is a win-win.”

Danny Boyce

Facilities and Business Manager of JBARB, Memorial University, N.L.

Partners

Featured Videos